Can you discuss the translational implications of the LEADER trial as it relates to the deployment of the GLP-1 receptor agonist liraglutide at the front lines of diabetes care?

Can you discuss the translational implications of the LEADER trial as it relates to the deployment of the GLP-1 receptor agonist liraglutide at the front lines of diabetes care?

Can you discuss the translational implications of the LEADER trial as it relates to the deployment of the GLP-1 receptor agonist liraglutide at the front lines of diabetes care? And what have we learned about its safety profile?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Itamar Raz, MD

Itamar Raz, MD

Professor of Internal Medicine
Head of the Diabetes Unit
Hadassah University Hospital
Jerusalem, Israel